JP Morgan Maintains Overweight on Revolution Medicines, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Overweight rating on Revolution Medicines (NASDAQ:RVMD) but lowered the price target from $47 to $39.

November 07, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan has maintained an Overweight rating on Revolution Medicines but lowered the price target from $47 to $39.
The news is directly related to Revolution Medicines and is likely to influence investor sentiment. While the Overweight rating suggests that JP Morgan expects the stock to outperform, the reduction in price target may create some uncertainty. However, the impact on the stock price is not clear cut and could be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100